1887

Abstract

(), otherwise known as ‘the pneumococcus’, is a fascinating microbe that continues to pose a significant problem to public health. Currently there are no specific National Institute for Clinical Excellence (NICE) or British Thoracic Society (BTS) clinical guidelines referring to the treatment of invasive pneumococcal infection. NICE clinical guidelines suggest the use of lytic β-lactam antibiotic regimens for the management of community-acquired pneumonia and bacterial meningitis; infections for which is a likely causative organism. Lytic antibiotics have been shown to increase the release of pneumolysin (the highly inflammatory and damaging toxin of the pneumococcus), thus theoretically increasing host damage, which may lead to a decline of clinical outcomes in vulnerable patients. In light of this information, should the use of non-lytic antibiotics, such as quinolones, rifamycins and macrolides, be considered for the treatment of invasive pneumococcal disease?

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000545
2017-08-01
2020-01-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/8/1253.html?itemId=/content/journal/jmm/10.1099/jmm.0.000545&mimeType=html&fmt=ahah

References

  1. Horaud T, Bouvet A, Leclercq R, de MH, Sicard M et al. Streptococci and the Host Springer Science & Business Media; 2013; pp.939
    [Google Scholar]
  2. WHO 2016; Pneumococcal disease. Available fromwww.who.int/ith/diseases/pneumococcal/en/
  3. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012;21:57–65 [CrossRef][PubMed]
    [Google Scholar]
  4. Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today?. Virulence 2014;5:20–26 [CrossRef][PubMed]
    [Google Scholar]
  5. NICE Clinial Knowledge Summaries 2016; Sepsis: recognition, diagnosis and early management. NICE Guideline. Available fromwww.nice.org.uk/guidance/ng51/chapter/recommendations#antibiotic-treatment-in-people-with-suspected-sepsis
  6. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 2012;25:409–419 [CrossRef][PubMed]
    [Google Scholar]
  7. Deaths Registered in England and Wales (Series DR) 2013; Office for National Statisitics Available fromhttps://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredinenglandandwalesseriesdr/2014-10-29 [cited 14 Sep 2015]
  8. Centre for Disease Control Pneumococcal epidemiology of vaccine preventable diseases Available fromwww.cdc.gov/vaccines/pubs/pinkbook/pneumo.html [cited 2016 Nov 19]
  9. Liu EY-M, Chang F-Y, Chang J-C, Fung C-P. Differences in virulence of pneumolysin and autolysin mutants constructed by insertion duplication mutagenesis and in-frame deletion in Streptococcus pneumoniae. BMC Biotechnol 2014;14:16–89 [CrossRef]
    [Google Scholar]
  10. Price KE, Greene NG, Camilli A. Export requirements of pneumolysin in Streptococcus pneumoniae. J Bacteriol 2012;194:3651–3660 [CrossRef][PubMed]
    [Google Scholar]
  11. Cole R. The production of methemoglobin by pneumococci. J Exp Med 1914;20:363–378 [CrossRef][PubMed]
    [Google Scholar]
  12. Bryant JC, Dabbs RC, Oswalt KL, Brown LR, Rosch JW et al. Pyruvate oxidase of Streptococcus pneumoniae contributes to pneumolysin release. BMC Microbiol 2016;16:271 [CrossRef][PubMed]
    [Google Scholar]
  13. Gilbert RJ, Sonnen AF. Measuring kinetic drivers of pneumolysin pore structure. Eur Biophys J 2016;45:365–376 [CrossRef][PubMed]
    [Google Scholar]
  14. Mitchell TJ, Andrew PW, Saunders FK, Smith AN, Boulnois GJ. Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein. Mol Microbiol 1991;5:1883–1888 [CrossRef][PubMed]
    [Google Scholar]
  15. Karmakar M, Katsnelson M, Malak HA, Greene NG, Howell SJ et al. Neutrophil IL-1β processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J Immunol 2015;194:1763–1775 [CrossRef][PubMed]
    [Google Scholar]
  16. Küng E, Coward WR, Neill DR, Malak HA, Mühlemann K et al. The pneumococcal polysaccharide capsule and pneumolysin differentially affect CXCL8 and IL-6 release from cells of the upper and lower respiratory tract. PLoS One 2014;9:e92355 [CrossRef][PubMed]
    [Google Scholar]
  17. Glas GJ, van der Sluijs KF, Schultz MJ, Hofstra JJ, van der Poll T et al. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemost 2013;11:17–25 [CrossRef][PubMed]
    [Google Scholar]
  18. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C.Pneumonia Guidelines Committee of the BTS Standards of Care Committee BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;643:1–55 [CrossRef][PubMed]
    [Google Scholar]
  19. Guidance and guidelines 2014; Pneumonia in adults: diagnosis and management. Available fromwww.nice.org.uk/guidance/cg191/chapter/1-recommendations#community-acquired-pneumonia-2 [cited 2016 Feb 18]
  20. Gupta D, Agarwal R, Aggarwal AN et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults. Lung Ind 2012;29:S27–S62[CrossRef]
    [Google Scholar]
  21. Guidance and guidelines 2015; Bacterial meningitis and meningococcal septicaemia. Available fromwww.nice.org.uk/guidance/cg102/evidence [cited 2016 Feb 18]
  22. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD et al. Infectious diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27–S72 [CrossRef][PubMed]
    [Google Scholar]
  23. Randle E, Ninis N, Inwald D. Invasive pneumococcal disease. Arch Dis Child Educ Pract Ed 2011;96:183–190 [CrossRef][PubMed]
    [Google Scholar]
  24. Gualerzi CO, Brandi L, Fabbretti A. 2013; Antibiotics: targets, mechanisms and resistance. Wiley; Available fromhttp://eu.wiley.com/WileyCDA/WileyTitle/productCd-3527333053.html cited 2016 Mar 15
  25. Pletz MW, Rohde GG, Welte T, Kolditz M, Ott S et al. Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000Res 2016;5:300 [CrossRef]
    [Google Scholar]
  26. Spreer A, Kerstan H, Böttcher T, Gerber J, Siemer A et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003;47:2649–2654 [CrossRef][PubMed]
    [Google Scholar]
  27. Böttcher T, Ren H, Goiny M, Gerber J, Lykkesfeldt J et al. Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J Neurochem 2004;91:1450–1460 [CrossRef][PubMed]
    [Google Scholar]
  28. Mccullers JA, English BK. Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol 2008;3:397–404 [CrossRef][PubMed]
    [Google Scholar]
  29. Lobanovska M, Pilla G. Penicillin's discovery and antibiotic resistance lessons for the future?. Yale J Biol Med 2017;90:135–145[PubMed]
    [Google Scholar]
  30. Fernández-Tornero C, García E, de Pascual-Teresa B, López R, Giménez-Gallego G et al. Ofloxacin-like antibiotics inhibit pneumococcal cell wall-degrading virulence factors. J Biol Chem 2005;280:19948–19957 [CrossRef][PubMed]
    [Google Scholar]
  31. Okumura R, Hoshino K, Otani T, Yamamoto T. Quinolones with enhanced bactericidal activity induce autolysis in Streptococcus pneumoniae. Chemotherapy 2009;55:262–269 [CrossRef][PubMed]
    [Google Scholar]
  32. Bretonnière C, Jozwiak M, Girault C, Beuret P, Trouillet JL et al. Rifampin use in acute community-acquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study. Crit Care 2015;19:303 [CrossRef][PubMed]
    [Google Scholar]
  33. Majhi A, Nandi A, Adhikary R, Mahanti S, Bishayi B. In vitro susceptibility of a penicillin-resistant and tolerable isolate of Streptococcus pneumoniae to combination therapy. J Infect Dev Ctries 2015;9:702–709 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000545
Loading
/content/journal/jmm/10.1099/jmm.0.000545
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error